SmPC - Olmesartan medoxomil 40mg Film coated Tablets: Change history
View Summary of Product Characteristics (SmPC - Olmesartan medoxomil 40mg Film coated Tablets)
Last updated on this site: 27 Mar 2025
To update sections 4.4, 4.8 of the SmPC and sections 2, 4 of the PIL to implement the signal recommendations on Angiotensin II receptor blockers (ARBs): azilsartan; candesartan; eprosartan; irbesartan; losartan; olmesartan; telmisartan; valsartan (single ingredient and fixed dose combinations) - Intestinal angioedema (EPITT no 20104) adopted at the 28-31 October 2024 PRAC meeting.
Last updated on this site: 27 Mar 2025
To update sections 4.4, 4.8 of the SmPC and sections 2, 4 of the PIL to implement the signal recommendations on Angiotensin II receptor blockers (ARBs): azilsartan; candesartan; eprosartan; irbesartan; losartan; olmesartan; telmisartan; valsartan (single ingredient and fixed dose combinations) - Intestinal angioedema (EPITT no 20104) adopted at the 28-31 October 2024 PRAC meeting.
-
Changes: (Updated: 27 Mar 2025)
To update sections 4.4, 4.8 of the SmPC and sections 2, 4 of the PIL to implement the signal recommendations on Angiotensin II receptor blockers (ARBs): azilsartan; candesartan; eprosartan; irbesartan; losartan; olmesartan; telmisartan; valsartan (single ingredient and fixed dose combinations) - Intestinal angioedema (EPITT no 20104) adopted at the 28-31 October 2024 PRAC meeting.
-
Changes: (Updated: 21 Sep 2022)
Initial upload